Brief: Kancera AB Revises Patent Strategy For Hdac-Project With Partner

Novakand Pharma AB

22/11/2019 07:22

Kancera AB  KANC.ST :
    * REVISES PATENT STRATEGY FOR HDAC-PROJECT WITH PARTNER
    * AND GRÜNENTHAL HAVE DECIDED FOR STRATEGIC REASONS TO
WITHDRAW
PATENT APPLICATION REGARDING SERIES OF HDAC INHIBITORS AND SEND
COMPLETED APPLICATION AT A LATER STAGE

Source text for Eikon:  ID:nWkr3jRTSr 
Further company coverage:  KANC.ST